Cowhage.

B6 is required for the conversion of L-DOPA to dopamine. The direction of the effect depends on where the conversion happens: added B6 accelerates peripheral decarboxylation, which increases dopamine outside the brain and leaves less L-DOPA available to cross into it. Anyone taking a prescribed levodopa product should regard this pairing as a reason to speak to their prescriber rather than as a stacking opportunity.

Tyrosine sits one step upstream of L-DOPA in the same pathway, but it competes with it for the same transporter at the gut and at the blood-brain barrier. Taking a substantial tyrosine dose alongside reduces how much L-DOPA gets through. Upstream on paper does not mean additive in practice when the two share a carrier.

A protein serving floods the LAT1 transporter with branched-chain and aromatic amino acids, which crowds out L-DOPA at both the intestine and the brain barrier. This is the same reason protein timing matters for prescribed levodopa. Separating the two by a couple of hours is the practical answer.

The catechol group binds ferric iron tightly and forms a complex that neither party absorbs well, so taking the two together lowers delivery of both. Separately, iron is required by tyrosine hydroxylase upstream in the pathway, which is a different relationship entirely and does not cancel the binding problem. Space the doses.

L-DOPA oxidises quickly once exposed to air and neutral pH, and ascorbate slows that by reducing the quinone back to the catechol. Formulators use it for shelf stability. Whether it changes anything after the capsule is swallowed is a separate and much weaker claim.

Catechins are themselves catechols and act as substrates and inhibitors of COMT, the enzyme that methylates L-DOPA and dopamine. Slowing that step raises exposure to the parent compound. The evidence is enzymatic and preclinical, and human confirmation with this seed is absent, so this should be read as mechanistic rather than clinical.

5-HTP and L-DOPA compete for the same decarboxylating enzyme, so loading one can lower conversion of the other and shift the balance between the two monoamine pools. Combining catecholamine and serotonin precursors is a poorly characterised situation and is not a routine pairing. Anyone on serotonergic or dopaminergic medication should keep this well away from a self-directed stack.

Tryptophan competes with L-DOPA both for transport across the blood-brain barrier and for the decarboxylation step once inside. The interaction runs in both directions, so each reduces the other's delivery. Practical effect is unpredictable and depends on relative dose.

Both catechol methylation and nicotinamide methylation are SAM-dependent, so a large load of one draws down the methyl pool available to the other. This is arithmetic on a shared cofactor rather than a receptor interaction. It matters most at high niacinamide doses, not at nutritional intakes.

COMT activity on catechols consumes SAM and generates homocysteine as a downstream product. Betaine feeds the remethylation arm that restores methionine and therefore SAM. The relationship is well described biochemically. It has not been shown to change any outcome in people taking this seed.